Advertisement

Topics

Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and ...

02:30 EDT 13 May 2019 | BioMedReports - Blog

  • Onconova to Receive $4 Million Upfront, including $2 Million Fee and $2 Million for Onconova Shares Purchased at a Premium, Plus up to $45.5 Million in Regulatory and Sales Milestones for Rigosertib in Greater China
  • HanX to Dedicate $2 Million in Local Currency to Invest in Greater China Rigosertib Clinical Development Over the Next 24 Months
  • Greater China Clinical Sites to Contribute to Current Global Phase 3 INSPIRE Study, Future Phase 3 Oral Rigosertib and Azacitidine Combination Study, and Future Lung Cancer Combination Studies Pursuant to a Joint Development Plan
  • Onconova to Present Rigosertib Data and Pivotal Clinical Trials at Acute Leukemia Forum in Shanghai on May 31, 2019

NEWTOWN, Pa., May 13, 2019 (GLOBE NEWSWIRE)

Read more...

Original Article: Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and ...

NEXT ARTICLE

More From BioPortfolio on "Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...